Robert Coffin
Fondateur chez REPLIMUNE GROUP, INC.
Fortune : 16 M $ au 30/06/2024
Postes actifs de Robert Coffin
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| REPLIMUNE GROUP, INC. | Directeur/Membre du Conseil | 01/03/2015 | - |
| Directeur Technique/Scientifique/R&D | - | - | |
| Fondateur | 01/03/2015 | - | |
| Directeur Général | 01/03/2015 | 09/01/2020 | |
| President | 01/03/2015 | 01/04/2024 |
Historique de carrière de Robert Coffin
Anciens postes connus de Robert Coffin
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| AMGEN INC. | Corporate Officer/Principal | 01/01/2011 | 01/01/2013 |
BioVex Ltd.
 BioVex Ltd. Miscellaneous Commercial ServicesCommercial Services BioVex Ltd. operates as a biotechnology firm. It focuses on the development and commercialization of biological treatments for cancer and the prevention of infectious disease. The company was founded on December 15, 1997 and is headquartered in Cambridge, the United Kingdom. | Directeur/Membre du Conseil | 01/01/1999 | 04/03/2011 |
| Directeur Technique/Scientifique/R&D | 01/01/1999 | 04/03/2011 | |
BioVex Group, Inc.
 BioVex Group, Inc. BiotechnologyHealth Technology BioVex Group, Inc. operates as a clinical-stage biotechnology company. It focuses on the development and commercialization of targeted treatments for cancer and the prevention of infectious disease. The company was founded in 1999 and is headquartered in Woburn, MA. | Directeur/Membre du Conseil | 01/01/1999 | 01/01/2011 |
| Directeur Technique/Scientifique/R&D | 01/01/1999 | 01/01/2011 | |
| Fondateur | 15/10/2009 | 01/01/2011 | |
BioVex, Inc.
 BioVex, Inc. Pharmaceuticals: MajorHealth Technology BioVex, Inc. develops vaccines for the treatment of cancer and the prevention of chronic infectious diseases. Its products include OncoVEX oncolytic and ImmunoVEX technology. The company was founded in 1999 by Dr. Robert Coffin and is headquartered in Woburn, MA. | Directeur/Membre du Conseil | 01/01/1999 | - |
| Directeur Technique/Scientifique/R&D | 01/01/1999 | - | |
| Fondateur | 01/01/1999 | - |
Formation de Robert Coffin
| Imperial College London | Doctorate Degree |
Statistiques
Internationale
| Etats-Unis | 5 |
| Royaume-Uni | 3 |
Opérationnelle
| Director/Board Member | 4 |
| Chief Tech/Sci/R&D Officer | 4 |
| Founder | 3 |
Sectorielle
| Health Technology | 5 |
| Commercial Services | 2 |
| Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| REPLIMUNE GROUP, INC. | Health Technology |
| AMGEN INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
BioVex Ltd.
BioVex Ltd. Miscellaneous Commercial ServicesCommercial Services BioVex Ltd. operates as a biotechnology firm. It focuses on the development and commercialization of biological treatments for cancer and the prevention of infectious disease. The company was founded on December 15, 1997 and is headquartered in Cambridge, the United Kingdom. | Commercial Services |
BioVex Group, Inc.
BioVex Group, Inc. BiotechnologyHealth Technology BioVex Group, Inc. operates as a clinical-stage biotechnology company. It focuses on the development and commercialization of targeted treatments for cancer and the prevention of infectious disease. The company was founded in 1999 and is headquartered in Woburn, MA. | Health Technology |
BioVex, Inc.
BioVex, Inc. Pharmaceuticals: MajorHealth Technology BioVex, Inc. develops vaccines for the treatment of cancer and the prevention of chronic infectious diseases. Its products include OncoVEX oncolytic and ImmunoVEX technology. The company was founded in 1999 by Dr. Robert Coffin and is headquartered in Woburn, MA. | Health Technology |
- Bourse
- Insiders
- Robert Coffin
- Expérience
